Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

ESMO Congress 2024 Highlights

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates Positive Safety, Signals of Biological Activity and Patients with Lasting Stable Disease

Trial in progress: A phase 1/2a trial of Aurora-A inhibitor (JAB-2485) in adult patients with advanced solid tumors

A Phase 1/2 study of Rinatabart Sesutecan (Rina-S) in Patients With Advanced Ovarian or Endometrial Cancer

Dazostinag (TAK-676) alone and in combination with pembrolizumab in patients with advanced/metastatic solid tumors: Data from phase 1 dose escalation

« Older Entries